Previous 10 | Next 10 |
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH PR Newswire Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior ...
2023-12-05 13:28:55 ET More on Olema Pharmaceuticals Olema Pharmaceuticals: Advancing On Multiple Fronts Olema: Two-Pronged Approach To Treat Breast Cancer Patients Olema Pharmaceuticals officer discloses sale of about 10K shares Seeking Alpha’s Quant ...
2023-12-05 04:57:41 ET Summary Novartis has upgraded mid-term sales guidance to 5% CAGR until 2027. The core operating margin target is at 40%, and this implies a 6.5% upgrade in our EPS estimates. We are still concerned about sales post-2027 due to patent expirations. Therefo...
2023-12-04 15:35:38 ET More on Blackstone Blackstone: Short-Term Upside May Be Capped (Rating Downgrade) Blackstone Vs. Apollo: The Winner Might Shock You Bumble to repurchase stock, interests from Blackstone for $100M Blackstone raises $2.6B for eighth real ...
2023-12-03 11:19:58 ET Summary Foreign stocks, particularly those with solid yields, are relatively cheap compared to the S&P 500. The Vanguard International High Dividend Yield Index Fund ETF Shares offers low valuation and solid long-term growth trends. VYMI has a high d...
2023-12-02 07:35:00 ET Summary Stocks are having their best November in 43 years, and stocks are now 13% historically overvalued. But thankfully, smart investors can always find incredible Warren Buffett-style bargains, both of the deep value and "wonderful company at a fair price...
2023-12-02 02:24:45 ET Summary AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. ImmunoGen's recent success with its drug ELAHERE, which received accelerated approval for the treatment of ovarian cance...
2023-11-28 11:52:30 ET Summary Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Tra...
2023-11-28 10:52:22 ET The U.S. Food and Drug Administration (FDA) on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies directed towards the proteins BCMA and CD19. The regulator said it had determined that ...
2023-11-28 05:48:31 ET Novartis ( NYSE: NVS ) has raised its mid-term sales growth target citing strong momentum of key growth drivers, majority of which are de-risked existing brands. Net sales is now expected to rise at a compound annual growth rate of 5% through 2027, compare...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...